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At the time of Cobalt, Brachytherapy was competing with surgery, 
considered as a mini invasive treatment with a high local control.  
At the time of conformal radiotherapy, BT was the optimal technique 
to deliver a high dose to the target while sparing the bone structures 
and salivary glands then reducing complications and xerostomia. But it 
was often considered as an operator dependent technique as surgery 
was. 
Today, at the time of high tech Radiotherapy, BT is still competing 
with non invasive treatment by irradiation, IMRT or Stereotactic RT. 
Nevertheless, BT maintains its specific advantages wich makes it the 
most conformal technique, delivering an accelerated and hyperfrac-
tionated technique of irradiation, then increasing the therapeutic 
ratio. The development of imaging for 3D dosimetry and Conformal 
BT, as well of the possibility to prescribe the dose rate and optimise 
the dose distribution improves the dose distribution and results of the 
technique. 
The intraoperative placement of the catheters in the target mimics 
fiducials and improves the delineation of the target combined to the 
imagines and clinical exam during the procedure. This contributes, as 
well as the implantation inside the tissues to reduce the target 
volume with no ITV and a PTV equal to the CTV. The irradiation 
directly in the target also reduces the dose transmited to the bone 
and the salivary glands as well as the nominal dose.  
Considering the treatment of oropharyngeal cancer, BT delivered as a 
boost after IMRT can be considered as the optimal combination of 
treatment, competitive with stereotactic techniques.  
Last but not least, on an economic point of view, BT is less expensive 
than new high tech external beam techniques.  
This justifies to intensify the teaching of this technique then offering 
to the patients a panel of skilled brachytherapists able to perform the 
procedure with quality assurance control.  
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About one third of oropharyngeal carcinomas are diagnosed in early-
stage disease, amendable to curative treatment with either radical 
surgery or primary radiotherapy (RT). However, two thirds of patients 
present with locally advanced disease (clinical stage III or IV) and have 
a less favorable prognosis. Over the last decades, the management of 
locally advanced HNC has evolved towards approaches that offer the 
possibility of organ preservation, such as chemoradiotherapy. 
Although the prognosis of patients treated with RT for locally 
advanced HNC is continually improving, loco regional failure remains a 
major concern, certainly for the HPV negative tumors. Locoregional 
recurrences are mainly located in the high-dose prescription regions, 
suggesting the need for even higher doses in those areas. However, 
dose escalation to an entire target volume is not possible due to 
normal tissue toxicity. Many studies have shown that we’re on the 
limit of acceptable toxicity with our current treatment strategies. The 
term ‘dose painting’ implies non-uniformity within a target region, 
directing dose to sub regions of tumour to improve local control. 
Focusing a high-dose boost to a biological target volume, such as the 
hypermetabolic area on a PET scan or volumes defined on functional 
imaging like DW-MRI, could improve response rates.  IMRT has the 
ability to deliver non-uniform dose distributions. 
The use of this highly conformal external beam radiotherapy allows us 
to sculpt the dose around these sub volumes within tumor. Since 
studies have shown that both the primary tumor and the lymh nodes 
are important sites of failure, a radiotherapy technique which can 
target both is beneficial. Using simultaneous integrated boost 
techniques, this can be done without increasing overall treatment 
time and at the same time take into account both primary tumor and 
involved nodes.  Moreover, concomitant administration of 
chemotherapy is feasible and often indicated in these advanced 
tumors. And lastly, with the use of sequential (functional)  imaging we 
can adapt the treatment plan during the course of radiotherapy, 
based on the biological response of the tumor. 
The advantages are in favour of the use of external beam 
radiotherapy for dose escalation in oropharyngeal carcinomas. 
However, good selection tools are needed to define the patients 
whom might benefit from dose escalation. Both functional imaging 
and molecular features warrant further investigation. These studies 
are currently proceeding in order to define these subgroups. 
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Purpose/Objective: A resent study Appelt et al. (Int J Radiat 
OncolBiol Phys, 2012) demonstrated a significant dose-response 
relationship for tumour regression after preoperative chemo-
radiotherapy for locally advanced rectal cancers. 
BT boost in combination with EBRT is one feasible way of increasing 
the total tumour dose. To spare the non-involved parts of the rectal 
wall during BT, a shieldable applicator is desirable. Hansen et al. (Med 
Phys, 2006) demonstrated that physical shielding is preferable 
compared to sparing by increasing the distance using a multi channel 
applicator. While shieldable applicators are commonly used in 
brachytherapy, no shieldable MRI-compatible applicator is 
commercially available. 
The purpose of this study was to describe dosimetric properties of a 
prototype shieldable MRI-compatible applicator and investigate the 
feasibility of performing dose calculations using a commercially 
available Treatment Planning System (TPS). 
Materials and Methods: A semi-solid applicator made of 
polyoxymethylene (POM) is shown in Figure 1. The cavity allows 
placement of an MRI-visible 'dummy' shield during an MRI-procedure, 
while a high-Z shield (90° or 180°) can be applied during irradiation. 
 
  
Dose measurements were performed with an 192Ir HDR-source 
(microSelectron, Nucletron, An Elekta Company) using the PFD3G diode 
and BluePhantom (iba Dosimetry GmbH). 
Immersing the applicator into water radial dose distributions were 
acquired for each 45°. Measurements were performed for the central 
catheter and for the applicator (with or without the shields) 
respectively and were compared with the radial dose distribution from 
the TPS Oncentra® Brachy 4.1 (Nucletron, An Elekta Company). 
Results: The agreement of the measurements and the TPS for the 
central catheter was excellent at distances 0.5 mm to 40.0 mm from 
the applicator surface (relative error from –2.0 % to 1.4 %). At larger 
distances, the TPS increasingly underestimated the dose with an error 
of approx -5 % at a distance of 60 mm. 
At clinical relevant distances (5 mm to 15 mm from the applicator 
surface) an under-dosage (2.1 % to 4.7 %) was found for the solid part 
of the applicator compared to the TPS estimations. Near the 
applicator surface the under-dosage was 10 %. At increasing distances 
the difference decreased eventually resulting in a small relative over-
dosage far from the surface. General over-dosage behaviour was 
found for the hollow part. This was approx 8 % near the surface, and 
in the range of 3.9 % to 8.3 % at the clinical relevant distances. 
Transmission factors (50 mm from the applicator) for the shields were 
0.34 and 0.31, respectively and were easily incorporated into the TPS. 
Conclusions: The dosimetric properties of the prototype applicator 
were found to be acceptable. In clinical practice a renormalisation of 
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the prescribed dose by 3.4 % due to the change in transmission and 
scatter condition should be considered. A POM insert for the hollow 
part of the applicator should be used when the shielding ability is not 
needed, in order to establish an isotropic dose distribution. 
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Purpose/Objective: Monte Carlo (MC) simulation in the patient 
geometry, as the latter is described by pretreatment CT image series, 
is a candidate dose calculation engine for individualized 
brachytherapy treatment planning, as well as a source of reference 
data for the benchmarking of advanced dose calculation algorithms 
beyond the TG43.  
Reducing MC calculation time while preserving results accuracy is 
beneficial in both contexts, and one of the common practices is the 
sub-sampling of the original images. This study reports initial results 
from employing an octree-based voxel compression method in MC 
dosimetry for brachytherapy patients. 
Materials and Methods: An application for preparing MC input files for 
a general purpose code (MCNP5 v.1.6) from information exported from 
a treatment planning station in the form of CT dicom images, RTDOSE, 
RTSTRUCT and RTPLAN has been developed. 
An octree-based indexing method was considered for importing the 
patient geometry as an alternative to standard approaches such as the 
lattice feature of the MCNP geometric package. 
According to this method a compression is achieved by combining 
voxels into octants provided that their difference in density is lower 
than a predefined density gradient threshold. The advantage of this 
method is that the highest resolution is maintained only in 
heterogeneous regions where high-density gradients are met. 
A representative breast 192Ir HDR patient CT image series (512x512x32) 
was selected, and the density of each voxel was obtained by applying 
the CT HU calibration. After voxel compression, the patient geometry 
can be imported into the MCNP code by defining the planes describing 
the octants in the octree based method. 
Results: Different density gradient thresholds were used for the 
representative breast case studied. Thresholds of 0.045 g/cm3, 0.067 
g/cm3 and 0.1 g/cm3 result to voxel number compressions of 70%, 80% 
and 88% relative to the original image series.  
As shown by the comparison of the image of an indicative plane in the 
original (a) and compressed (b) geometry for the 0.1 g/cm3  threshold, 
some information loss occurs along with CT noise filtering for density 




Conclusions: A robust octree-based indexing has been developed and 
proved to be an efficient method for sub-sampling image data 
required for patient specific MC dosimetry in brachytherapy in 
agreement with previous findings in the literature. 
The dosimetric accuracy versus the calculation time efficiency 
achieved for different density gradient thresholds, as well as the 
comparison to alternative MCNP strategies (i.e.lattice feature 
employing the speed tally option) is work in progress 
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Purpose/Objective: Modern treatment planning systems (TPS) for 
brachytherapy are now available that are based on model-based dose 
calculation algorithms (MBDCA). They enable heterogeneity 
corrections which are needed to replace the TG43 water dose 
formalism with a more accurate approach. With the aim of evaluating 
differences between two TPS regarding the impact of heterogeneities 
such as applicators and tissues in a clinical case, five gynecological 
brachytherapy treatment plans were compared.  
Materials and Methods: The treatment planning was done using a 
commercial TPS (BrachyVision™(BV), Varian). The plan was created for 
a Gammamed Plus source, 17 dwell positions and a prescribed dose of 
7.5 Gy at 0.5 cm from the applicator, which consists of a hollow 
plastic cylinder with external diameter of 3.5 cm and 0.4 cm wall 
thickness. The applicator was contoured using CT images of the 
applicator only (1mm3 voxel size) and then inserted in a real patient 
image using rigid image registration (Fig. 1.a and 1.b) considering its 
real composition. A water-based applicator was used to study tissue 
effect in a separate calculation. BV was used to obtain Dw,w (TG43) 
and also Dw,m through a grid based Boltzmann solver, ACUROS™ (AC), 
which can handle heterogeneities. The dose distributions were then 
compared to results (Dw,m) obtained with a Monte Carlo (MC) code, 
MCNP5, with tissue compositions provided by AC and the applicator 
defined through an analytical geometry. Simulation uncertainty (1σ) 
was lower than 1% inside the 50% isodose region. 
Results: AC and MC results compared with TG43 presented differences 
up to 17% with mean difference inside the 100% isodose region of 5.2 
±1.2% and 5.3±1.5% (Fig. 1.c), respectively. These differences are 
mainly due to the air gap inside the applicator since the mean 
difference inside the 100% isodose region when using a homogeneous 
water applicator is about 1%. AC and MC presented good agreement 
with differences (Fig. 1.d) lower than 2% and 5% for 79% and 93% of 
the voxels of the scoring volume (Fig. 1.b), respectively. The mean 
differences between the Dw,m values (AC and MC) were also calculated 
separately for each tissue (bone, muscle and adipose tissue) and are 
within 1.0±0.1%, which represents no significant differences due the 
tissue composition. However, some regions show differences of about 
10% (Fig. 1d), especially near the applicator’s tip which can be 
partially attributed to the algorithm employed by AC which solves the 
Boltzmann equation by discretizing its six variables.  
 
Conclusions: The effect of heterogeneities can be significant due to 
the applicator considered in this case and it seems to be a relevant 
aspect due several types of applicators commercially available. AC 
and MC have shown similar results with no apparent dependence of 
the tissue, however, dose differences can be higher in some regions 
which need to be evaluated in more detail. 
 
 
